<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090424</url>
  </required_header>
  <id_info>
    <org_study_id>CP-003</org_study_id>
    <nct_id>NCT04090424</nct_id>
  </id_info>
  <brief_title>Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns</brief_title>
  <official_title>A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyNovo Biomaterials Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>PolyNovo Biomaterials Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, pivotal study to assess the safety and effectiveness of a new method&#xD;
      of treating severe burns using NovoSorb Biodegradable Temporizing Matrix (BTM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, pivotal study to assess the safety and effectiveness of a new method&#xD;
      of treating severe burns using NovoSorb Biodegradable Temporizing Matrix (BTM). A comparison&#xD;
      will be made between burn wounds treated with BTM and the institution's standard of care&#xD;
      (SOC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of study lesions in both groups with complete wound closure after skin grafting</measure>
    <time_frame>4 weeks after skin grafting</time_frame>
    <description>Assessment of clinical outcome by wound closure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>NovoSorb BTM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of NovoSorb BTM to study lesions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of the institution's standard to care to study lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoSorb BTM</intervention_name>
    <description>NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.</description>
    <arm_group_label>NovoSorb BTM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.</description>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent directly or via legal representative prior to any&#xD;
             clinical study procedures being performed&#xD;
&#xD;
          2. Willing to comply with all study procedures and expects to be available for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male and females ≥ 21 years of age and ≤ 70 years of age&#xD;
&#xD;
          4. Patients with deep dermal or full thickness burns between 5% and 50%, inclusive, of&#xD;
             their total body surface area (TBSA).&#xD;
&#xD;
             Types of burns include the following:&#xD;
&#xD;
               -  Scalding including from hot water, cooking oil, grease&#xD;
&#xD;
               -  Flame&#xD;
&#xD;
               -  Flash&#xD;
&#xD;
               -  Contact&#xD;
&#xD;
          5. Subjects who have staged surgical procedures planned e.g., one procedure to excise the&#xD;
             burn injury and a later procedure to prepare the wound bed and apply an autologous&#xD;
             skin graft.&#xD;
&#xD;
          6. The minimum total area across all lesions to have NovoSorb® BTM applied is 5% BSA&#xD;
&#xD;
          7. Females, who are non-pregnant, naturally postmenopausal, or who agree to use effective&#xD;
             contraceptive methods throughout the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a known hypersensitivity to polyurethane&#xD;
&#xD;
          2. Only a non-burn injury has been experienced by the subject including soft-tissue&#xD;
             degloving and friction burn/crush, i.e., road rash&#xD;
&#xD;
          3. Multiple traumas, i.e., significant traumatic injury to a solid organ in addition to&#xD;
             skin&#xD;
&#xD;
          4. Presence of a medical condition with a life expectancy of less than 12 months, such as&#xD;
             advanced malignancy&#xD;
&#xD;
          5. Presence of a medical condition that might interfere with treatment evaluation; or&#xD;
             require a change in therapy including but not limited to, significant immune&#xD;
             deficiency, or skin or vascular diseases in the area of the wound&#xD;
&#xD;
          6. For females - has known or suspected pregnancy, planned pregnancy, or during lactation&#xD;
&#xD;
          7. Has exposure to any other investigational agent within the last 6 months&#xD;
&#xD;
          8. Has exposure to any other treatment/device that will interfere with NovoSorb® BTM&#xD;
             integration&#xD;
&#xD;
          9. Anticipated inability to perform wound care and follow-up procedures&#xD;
&#xD;
         10. Anticipates of a level of non-compliance&#xD;
&#xD;
         11. The use of off-label treatments for full-thickness / deep-dermal burns is not&#xD;
             permitted&#xD;
&#xD;
         12. Clinical signs of wound infection at areas to be potentially treated using NovoSorb®&#xD;
             BTM that in the opinion of the investigator may compromise safety and study objectives&#xD;
&#xD;
         13. The use of NovoSorb® BTM on the face and in the perineum area is not permitted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Wagstaff, MBBS, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Royal Adelaide Hospital, Adelaide SA 5000. Australia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Bradbury</last_name>
    <phone>+1(949) 542-0950</phone>
    <email>kim.b@polynovo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valleywise Health</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida, Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center, New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital /Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>24157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University/ Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Medical Center, and the Oregon Burn Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital and Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UW Health University Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.polynovo.com.au/</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

